Vaxart Announces Preliminary Topline Data From Dose-Ranging Phase 2 Study Of Its Bivalent Norovirus Vaccine Candidate
Portfolio Pulse from Happy Mohamed
Vaxart, Inc. (NASDAQ:VXRT) announced positive preliminary topline data from the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. The vaccine met all primary endpoints, showing robust serum immune responses across all doses. The company expects topline data from Phase 2 GI.1 challenge study in Q3 2023. The data will inform dosage levels in a larger Phase 2b study and support an End-of-Phase 2 meeting with the FDA.
July 06, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart's positive preliminary results from the Phase 2 clinical trial of its norovirus vaccine candidate could boost investor confidence and potentially impact the company's stock positively in the short term.
Positive clinical trial results are typically seen as a positive indicator for biotech companies like Vaxart, as they suggest progress towards regulatory approval and potential future revenue. This news could therefore lead to increased investor confidence and a potential rise in Vaxart's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100